Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

Number of employees : 306 people.
Sales per Businesses
20172018Delta
CHF (in Million)%CHF (in Million)%
MMX Products40.3254%31.7741.9% -21.2%
Royalties20.0626.9%16.9022.3% -15.76%
Generic Products and Specialty Drugs9.1712.3%8.9811.8% -2.12%
Marketed Products - Eleview1.742.3%7.8010.3% +348.29%
Licence Fees, Up - front Fees and Milestones1.672.2%6.598.7% +295.54%
Other Revenues from Sales0.8941.2%1.091.4% +22.09%
Related Services0.8021.1%2.633.5% +228.42%
Sales per Regions
20172018Delta
CHF (in Million)%CHF (in Million)%
Italy74.65100%75.76100% +1.49%
Managers
NameAgeSinceTitle
Alessandro E. Della Chà552014Chief Executive Officer & Executive Director
Mauro Severino Ajani632006Chairman
Giuseppe Cipriano612001Chief Operating Officer
Niall Donnelly44-Chief Financial Officer & Head-Investor Relations
Luigi Moro671999Chief Scientific Officer
Davide Malavasi45-Director-Qualified Person & Technical
Kevin Joseph Donovan592016Independent Non-Executive Director
Dieter A. Enkelmann602006Independent Non-Executive Director
Maria Grazia Roncarolo, Dr.642012Independent Non-Executive Director
Hans Christoph Tanner, Dr.68-Executive Director & Head-Transactions Office
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 0 15,037,483 6,200,345 41.2% 251,637 1.7% 41.2%
Shareholders
NameEquities%
Mauro Severino Ajani 5,571,209 37.0%
Gerald Herz 1,252,984 8.33%
dievini Hopp BioTech holding GmbH & Co. KG 786,361 5.23%
AMG Fondsverwaltung AG 473,594 3.15%
Cosmo Pharmaceuticals N.V. 451,909 3.01%
UBS Asset Management Switzerland AG 306,077 2.04%
The Vanguard Group, Inc. 196,480 1.31%
Baillie Gifford & Co. 121,349 0.81%
Bellevue Asset Management AG 106,161 0.71%
Norges Bank Investment Management 105,765 0.70%
Holdings
NameEquities%Valuation
Cassiopea S.p.A. (SKIN) 4,508,98745.1%188,598,256 USD
Cosmo Pharmaceuticals N.V. (COPN) 451,9093.01%34,096,100 USD
Paion AG (PA8) 5,238,2258.19%11,522,471 USD
Company contact information
Cosmo Pharmaceuticals NV
Riverside II
Sir John Rogerson's Quay
Dublin 2

Phone : +353.1.8170370
Fax : +353.1.8230718
Web : http://www.cosmopharma.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.-16.38%1 093
JOHNSON & JOHNSON9.55%372 094
ROCHE HOLDING AG24.22%261 287
MERCK AND COMPANY16.73%227 076
PFIZER-12.19%212 123
NOVARTIS22.85%210 097
BRISTOL-MYERS SQUIBB COMPANY22.78%149 606
AMGEN21.61%140 667
NOVO NORDISK AS28.05%134 124
ABBVIE-4.72%129 900
ASTRAZENECA22.88%126 265
SANOFI17.83%124 253
ELI LILLY AND COMPANY5.02%116 685
GLAXOSMITHKLINE15.68%113 859
BAYER AG17.26%77 599
TAKEDA PHARMACEUTICAL COMPANY LIMITED22.27%63 134
ALLERGAN PLC40.91%61 828
JIANGSU HENGRUI MEDICINE CO., LTD.61.33%54 804
CHUGAI PHARMACEUTICAL CO., LTD.62.46%50 329
DAIICHI SANKYO COMPANY, LIMITED119.21%44 545
ASTELLAS PHARMA INC.36.75%32 384